Table 2.
Clinical features of PDAC patients
| PDAC | % | ||
| Characteristics | |||
| Female | 18 | 45.0 | |
| Male | 22 | 55.0 | |
| Age (y) | |||
| Mean | 69 | ||
| Range | 41–84 | ||
| Stage | |||
| IA | 2 | 5.0 | |
| IB | 1 | 2.5 | |
| IIA | 9 | 22.5 | |
| IIB | 26 | 65.0 | |
| III | 2 | 5.0 | |
| Grading | |||
| 1 | 2 | 5.0 | |
| 2 | 19 | 47.5 | |
| 3 | 19 | 47.5 | |
| Primary site | |||
| Head | 32 | 80.0 | |
| Body | 3 | 7.5 | |
| Tail | 2 | 5.0 | |
| Body-Tail | 3 | 7.5 | |
| Baseline CA19.9 (IU/ml) | |||
| Evaluated in | 36 | 90.0 | |
| Mean | 221.7 | ||
| Median | 78.5 | ||
| Range | 1–1209 |
Rounded percentage; Classified according to the TMN classification of malignant tumor of the pancreas (UICC).